TY -的T1低剂量口服糖皮质激素在哮喘的同事增加发病率和死亡率JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.03054 -2021欧元六世- 60 - 3 SP - 2103054 AU -英奇Raadal Skov盟Hanne马德森AU -丹尼尔Pilsgaard亨利AU -雅各布Harbo安徒生盟-安东Pottegard盟Jesper Rømhild Davidsen Y1 - 2022/09/01 UR - //www.qdcxjkg.com/content/60/3/2103054.abstract N2 -背景长期口服皮质类固醇(OCS)治疗严重哮喘是造成重大不利影响,但低风险的一般知识的影响哮喘的数量是有限的。我们旨在探索在一个全国性的丹麦人口哮喘。方法的用户哮喘药物成熟女性年龄在18 - 45年被确定在1999 - 2018年在丹麦全国注册,之后在open-cohort前瞻性的设计。商务用户事件被倾向得分匹配1:4使用者与更换。口服避孕药使用和事件之间的关联并发症被Cox回归检验。死亡率、死因和计划外医院进行了评估。结果商务用户(n = 352),相比之下,使用者(n = 121 408),所有结果的风险增加明显的剂量反应关系开始累积剂量的≤500毫克(prednisolone-equivalent)。风险比率范围从1.24 (95% CI 1.18 - -1.30)为骨折为8.53 (95% CI 3.97 - -18.33)肾上腺机能不全。抑郁/焦虑发生率最高的差异为4.3 (95% CI 3.6 - -5.0)每1000人每年。Asthma-specific死亡率通常是低为0.15 (95% CI 0.11 - -0.20)和0.04 (95% CI 0.02 - -0.06)每1000人每年为商务用户和使用者,分别。 Mortality rates and unscheduled hospital visits increased with increasing OCS exposure.Conclusion The study findings should be interpreted with their observational nature in mind. However, we found that even at low cumulative exposure, OCS use in asthma management was associated with increased risk of comorbidities, mortality and unscheduled hospital visits. Effective strategies for optimising asthma control and reducing OCS use are pivotal in asthma management.Oral corticosteroid use in asthma treatment is associated with an increase in morbidity and mortality even after low cumulative doses of ≤500 mg (prednisolone-equivalent) and with evidence of dose–response relationships https://bit.ly/3gBSEAB ER -